THE WHAT? AstraZeneca has agreed a major obesity-focused licensing deal with China’s CSPC Pharmaceutical Group, worth up to US$18.5 billion, as it accelerates its push into the fast-growing weight-loss market.

THE DETAILS Under the agreement, AstraZeneca will pay US$1.2 billion upfront for rights to eight obesity drug candidates, including four injectable therapies. The deal gives AstraZeneca ex-China rights to CSPC’s most advanced compound, SYH2082, which targets both GLP-1 and GIP hormones and is set to enter human trials.

AstraZeneca will also gain access to CSPC’s long-acting peptide technology, which could enable monthly dosing—seen as a key competitive advantage over current weekly injections. CSPC is eligible for up to US$3.5 billion in development and regulatory milestones and up to US$13.8 billion in sales-related payments.

THE WHY? The agreement strengthens AstraZeneca’s position in obesity and metabolic disease, as drugmakers race to develop more convenient and affordable alternatives to current GLP-1 therapies. Longer-acting treatments could address adherence challenges in the category, while the deal also reinforces AstraZeneca’s broader strategy to deepen its R&D and commercial footprint in China.

Source: Bloomberg

The post AstraZeneca signs up to US$18.5 billion obesity drug deal with China’s CSPC appeared first on Global Cosmetics News.